120 related articles for article (PubMed ID: 37586075)
21. Germ-line and rearranged Tcrd transcription distinguish bona fide NK cells and NK-like gammadelta T cells.
Stewart CA; Walzer T; Robbins SH; Malissen B; Vivier E; Prinz I
Eur J Immunol; 2007 Jun; 37(6):1442-52. PubMed ID: 17492716
[TBL] [Abstract][Full Text] [Related]
22. The IKZF1-IRF4/IRF5 Axis Controls Polarization of Myeloma-Associated Macrophages.
Mougiakakos D; Bach C; Böttcher M; Beier F; Röhner L; Stoll A; Rehli M; Gebhard C; Lischer C; Eberhardt M; Vera J; Büttner-Herold M; Bitterer K; Balzer H; Leffler M; Jitschin S; Hundemer M; Awwad MHS; Busch M; Stenger S; Völkl S; Schütz C; Krönke J; Mackensen A; Bruns H
Cancer Immunol Res; 2021 Mar; 9(3):265-278. PubMed ID: 33563611
[TBL] [Abstract][Full Text] [Related]
23. Diet-induced obesity reduces bone marrow T and B cells and promotes tumor progression in a transplantable Vk*MYC model of multiple myeloma.
Nedal TMV; Moen SH; Roseth IA; Tryggestad SS; Aass KR; Hov GG; Hella H; Sponaas AM; Standal T
Sci Rep; 2024 Feb; 14(1):3643. PubMed ID: 38351079
[TBL] [Abstract][Full Text] [Related]
24. In vitro expansion of gamma delta T cells with anti-myeloma cell activity by Phosphostim and IL-2 in patients with multiple myeloma.
Burjanadzé M; Condomines M; Reme T; Quittet P; Latry P; Lugagne C; Romagne F; Morel Y; Rossi JF; Klein B; Lu ZY
Br J Haematol; 2007 Oct; 139(2):206-16. PubMed ID: 17897296
[TBL] [Abstract][Full Text] [Related]
25. γδ Intraepithelial Lymphocyte Migration Limits Transepithelial Pathogen Invasion and Systemic Disease in Mice.
Edelblum KL; Singh G; Odenwald MA; Lingaraju A; El Bissati K; McLeod R; Sperling AI; Turner JR
Gastroenterology; 2015 Jun; 148(7):1417-26. PubMed ID: 25747597
[TBL] [Abstract][Full Text] [Related]
26. CD4+ T-cell killing of multiple myeloma cells is mediated by resident bone marrow macrophages.
Haabeth OAW; Hennig K; Fauskanger M; Løset GÅ; Bogen B; Tveita A
Blood Adv; 2020 Jun; 4(12):2595-2605. PubMed ID: 32544236
[TBL] [Abstract][Full Text] [Related]
27. [Influence of thalidomide on bone marrow microenvironment in refractory and relapsed multiple myeloma].
Li J; Luo SK; Hong WD; Zhou ZH; Zou WY
Ai Zheng; 2003 Apr; 22(4):346-9. PubMed ID: 12703985
[TBL] [Abstract][Full Text] [Related]
28. Gamma delta T cells are activated by polysaccharide K (PSK) and contribute to the anti-tumor effect of PSK.
Inatsuka C; Yang Y; Gad E; Rastetter L; Disis ML; Lu H
Cancer Immunol Immunother; 2013 Aug; 62(8):1335-45. PubMed ID: 23685781
[TBL] [Abstract][Full Text] [Related]
29. Myeloperoxidase creates a permissive microenvironmental niche for the progression of multiple myeloma.
Williams CMD; Noll JE; Bradey AL; Duggan J; Wilczek VJ; Masavuli MG; Grubor-Bauk B; Panagopoulos RA; Hewett DR; Mrozik KM; Zannettino ACW; Vandyke K; Panagopoulos V
Br J Haematol; 2023 Nov; 203(4):614-624. PubMed ID: 37699574
[TBL] [Abstract][Full Text] [Related]
30. Neoplastic plasma cells generate an inflammatory environment within bone marrow and markedly alter the distribution of T cells between lymphoid compartments.
Goodyear OC; Essex S; Seetharam A; Basu S; Moss P; Pratt G
Oncotarget; 2017 May; 8(18):30383-30394. PubMed ID: 28389623
[TBL] [Abstract][Full Text] [Related]
31. Myeloma Cells Are Activated in Bone Marrow Microenvironment by the CD180/MD-1 Complex, Which Senses Lipopolysaccharide.
Kikuchi J; Kuroda Y; Koyama D; Osada N; Izumi T; Yasui H; Kawase T; Ichinohe T; Furukawa Y
Cancer Res; 2018 Apr; 78(7):1766-1778. PubMed ID: 29363546
[TBL] [Abstract][Full Text] [Related]
32. Human Vdelta1 gamma-delta T cells exert potent specific cytotoxicity against primary multiple myeloma cells.
Knight A; Mackinnon S; Lowdell MW
Cytotherapy; 2012 Oct; 14(9):1110-8. PubMed ID: 22800570
[TBL] [Abstract][Full Text] [Related]
33. Tumor-infiltrating IL-17-producing gammadelta T cells support the progression of tumor by promoting angiogenesis.
Wakita D; Sumida K; Iwakura Y; Nishikawa H; Ohkuri T; Chamoto K; Kitamura H; Nishimura T
Eur J Immunol; 2010 Jul; 40(7):1927-37. PubMed ID: 20397212
[TBL] [Abstract][Full Text] [Related]
34. Modeling multiple myeloma-bone marrow interactions and response to drugs in a 3D surrogate microenvironment.
Belloni D; Heltai S; Ponzoni M; Villa A; Vergani B; Pecciarini L; Marcatti M; Girlanda S; Tonon G; Ciceri F; Caligaris-Cappio F; Ferrarini M; Ferrero E
Haematologica; 2018 Apr; 103(4):707-716. PubMed ID: 29326121
[TBL] [Abstract][Full Text] [Related]
35. Cell-cell contact between marrow stromal cells and myeloma cells via VCAM-1 and alpha(4)beta(1)-integrin enhances production of osteoclast-stimulating activity.
Michigami T; Shimizu N; Williams PJ; Niewolna M; Dallas SL; Mundy GR; Yoneda T
Blood; 2000 Sep; 96(5):1953-60. PubMed ID: 10961900
[TBL] [Abstract][Full Text] [Related]
36. CD4+CD25+FOXP3+ T regulatory cells reconstitute and accumulate in the bone marrow of patients with multiple myeloma following allogeneic stem cell transplantation.
Atanackovic D; Cao Y; Luetkens T; Panse J; Faltz C; Arfsten J; Bartels K; Wolschke C; Eiermann T; Zander AR; Fehse B; Bokemeyer C; Kroger N
Haematologica; 2008 Mar; 93(3):423-30. PubMed ID: 18287134
[TBL] [Abstract][Full Text] [Related]
37. Role of Immunotherapy in Targeting the Bone Marrow Microenvironment in Multiple Myeloma: An Evolving Therapeutic Strategy.
Chung C
Pharmacotherapy; 2017 Jan; 37(1):129-143. PubMed ID: 27870103
[TBL] [Abstract][Full Text] [Related]
38. Dual inhibition of mTORC1/2 by DCZ0358 induces cytotoxicity in multiple myeloma and overcomes the protective effect of the bone marrow microenvironment.
Gao L; Li B; Yang G; Liu P; Lan X; Chang S; Tao Y; Xu Z; Xie B; Sun X; Wang Y; Hu L; Yu D; Xie Y; Bu W; Wu X; Zhu W; Shi J
Cancer Lett; 2018 May; 421():135-144. PubMed ID: 29428642
[TBL] [Abstract][Full Text] [Related]
39. Targeting of CXCR3 improves anti-myeloma efficacy of adoptively transferred activated natural killer cells.
Bonanni V; Antonangeli F; Santoni A; Bernardini G
J Immunother Cancer; 2019 Nov; 7(1):290. PubMed ID: 31699153
[TBL] [Abstract][Full Text] [Related]
40. Growth Response and Differentiation of Bone Marrow-Derived Mesenchymal Stem/Stromal Cells in the Presence of Novel Multiple Myeloma Drug Melflufen.
Gebraad A; Ohlsbom R; Miettinen JJ; Emeh P; Pakarinen TK; Manninen M; Eskelinen A; Kuismanen K; Slipicevic A; Lehmann F; Nupponen NN; Heckman CA; Miettinen S
Cells; 2022 May; 11(9):. PubMed ID: 35563880
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
